Hepaximin 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Aristopharma ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. Shows broad spectrum activity against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- Traveler's Diarrhea: For patients ≥12 years of age: 200 mg 3 times daily for 3 days.
- Hepatic Encephalopathy: For patients ≥18 years of age: 550 mg 2 times daily.
- Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food.
Interaction
Hepaximin induces CYP3A4 in vitro, but at the recommended dosing regimen is not expected to induce CYP3A4 in patients with normal liver function.
Contraindications
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product.
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk or not.
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Consider discontinuation if diarrhea symptoms worsen or persist for more than 24-48 hours
- Pseudomembranous colitis has been reported with nearly all antibacterial agents
Use in Special Populations
- Renal Impairment: The pharmacokinetics of Hepaximin in patients with impaired renal function has not been studied.
- Hepatic Impairment: The systemic exposure of Hepaximin was markedly elevated in patients with hepatic impairment compared to healthy subjects.
Overdose Effects
No specific information is available on the treatment of over dosage with Hepaximin. In case of over dosage, discontinue Hepaximin, treat symptomatically and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.